Safety, efficacy, and immunogenicity of a Salmonella Paratyphi A vaccine
Safety, efficacy, and immunogenicity of a Salmonella Paratyphi A vaccine
Background: Salmonellaenterica serovar Paratyphi A (also known as S. Paratyphi A) is responsible for more than 2 million cases of enteric fever annually. There are no licensed vaccines against S. Paratyphi A.
Methods: in a double-blind, randomized, placebo-controlled trial, we evaluated an orally administered live, attenuated S. Paratyphi A vaccine (CVD 1902) using a controlled human infection model. Healthy U.K. adults were assigned in a 1:1 ratio to receive two doses of CVD 1902 or placebo 14 days apart. Twenty-eight days after the second dose, participants were challenged orally with S. Paratyphi A. The primary end point was a diagnosis of S. Paratyphi A infection within 14 days after challenge. Secondary end points included safety and immunogenicity.
Results: a total of 72 participants underwent randomization, of whom 34 in the CVD 1902 group and 36 in the placebo group were challenged with S. Paratyphi A. The median age of the participants was 32 years (range, 20 to 54), and 46% were women. The number of adverse events was generally similar in the two groups, and no vaccine-related serious adverse events were identified. CVD 1902 induced serum IgG and IgA responses to the O antigen of S. Paratyphi A. No increases in serum IgG or IgA titers occurred in the placebo group. In the intention-to-treat population, an S. Paratyphi A infection was diagnosed within 14 days after challenge in 21% of the participants in the CVD 1902 group and in 75% of those in the placebo group (P<0.001), resulting in a vaccine efficacy of 73% (95% confidence interval [CI], 46 to 86). The vaccine efficacy was 69% (95% CI, 42 to 84) in the per-protocol analysis.
Conclusions: in healthy U.K. adults who were challenged with S. Paratyphi A in a controlled human infection model, a two-dose series of CVD 1902 led to protection against S. Paratyphi A infection without safety concerns.
Bacterial Infections, Global Health, Infectious Disease, Infectious Disease General, Vaccines
1704-1714
McCann, Naina
5cda7cdb-78a3-41e7-b32f-1ae0cb0c53c4
Vicentine, Margarete Paganotti
3127eb1f-7c24-463d-80e4-113bc3b84368
Ebrahimi, Narges
f9a077b3-ebf4-4cde-81e4-52650cf25983
Greenland, Melanie
f1ad44ed-4d20-4800-9d91-89a103a46182
Angus, Brian
24f9d013-2967-4282-81b0-23d4528d49fd
Collins, Andrea M.
7c571856-429e-48f9-9e72-d70911ac9509
Darton, Thomas
563cb98c-d30e-49d6-b71e-b291afa586db
Emary, Katherine
dd588fbe-d37a-44ac-a5f6-5f44c48fbfd5
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Flaxman, Amy
1227d180-aaca-4958-bb5a-d6fd5e788c21
Maria, Noshi
b0b9da3c-bbfa-4dfe-987d-7fe2ca4408e1
Green, Christopher A.
4940709e-a083-44ae-812a-60af3c468811
Molina, Claudia Juarez
3e123c11-58e8-4928-9492-a43a4d72ab4f
Paidisetti, Ravindra
df44801c-537d-41b5-ba85-d7d2ea23a898
Lazarus, Rajeka
9cef06db-d282-42b9-85fe-5ae26bdf6813
Macaulay, Grace C.
a56c73ac-fab1-4b72-873c-2829f10a39cf
McLean, Florence
6652a87b-6892-49a9-b181-4c3ea675e9be
Mohan, V. Krishna
c1783c97-5e5d-4ab0-97e7-62dacddfaa28
Naidu, M. Gangadhara
2ae99d63-6163-4f0e-9a4c-3524b4e8d92d
Ramasamy, Maheshi N.
ae42fa67-f3e2-430a-81da-92d601b96b79
Rao, D. Yogeswara
215a3944-15e1-4f68-82d8-dc2604c81dec
Singh, Nisha
6efdfb3b-0148-4874-94eb-b8440c9922eb
Vernon, Sophie
65901690-5d37-4df3-b990-b060f8edc3fe
Kim, Young Chan
ce52e423-13b2-4b5e-aea1-36ede5e76078
Levine, Myron M.
0596c5bc-2165-45f7-917f-90b53ee9fb54
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Pollard, Andrew J.
3057c98b-3868-4bbb-a69f-f4660c2afd93
30 October 2025
McCann, Naina
5cda7cdb-78a3-41e7-b32f-1ae0cb0c53c4
Vicentine, Margarete Paganotti
3127eb1f-7c24-463d-80e4-113bc3b84368
Ebrahimi, Narges
f9a077b3-ebf4-4cde-81e4-52650cf25983
Greenland, Melanie
f1ad44ed-4d20-4800-9d91-89a103a46182
Angus, Brian
24f9d013-2967-4282-81b0-23d4528d49fd
Collins, Andrea M.
7c571856-429e-48f9-9e72-d70911ac9509
Darton, Thomas
563cb98c-d30e-49d6-b71e-b291afa586db
Emary, Katherine
dd588fbe-d37a-44ac-a5f6-5f44c48fbfd5
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Flaxman, Amy
1227d180-aaca-4958-bb5a-d6fd5e788c21
Maria, Noshi
b0b9da3c-bbfa-4dfe-987d-7fe2ca4408e1
Green, Christopher A.
4940709e-a083-44ae-812a-60af3c468811
Molina, Claudia Juarez
3e123c11-58e8-4928-9492-a43a4d72ab4f
Paidisetti, Ravindra
df44801c-537d-41b5-ba85-d7d2ea23a898
Lazarus, Rajeka
9cef06db-d282-42b9-85fe-5ae26bdf6813
Macaulay, Grace C.
a56c73ac-fab1-4b72-873c-2829f10a39cf
McLean, Florence
6652a87b-6892-49a9-b181-4c3ea675e9be
Mohan, V. Krishna
c1783c97-5e5d-4ab0-97e7-62dacddfaa28
Naidu, M. Gangadhara
2ae99d63-6163-4f0e-9a4c-3524b4e8d92d
Ramasamy, Maheshi N.
ae42fa67-f3e2-430a-81da-92d601b96b79
Rao, D. Yogeswara
215a3944-15e1-4f68-82d8-dc2604c81dec
Singh, Nisha
6efdfb3b-0148-4874-94eb-b8440c9922eb
Vernon, Sophie
65901690-5d37-4df3-b990-b060f8edc3fe
Kim, Young Chan
ce52e423-13b2-4b5e-aea1-36ede5e76078
Levine, Myron M.
0596c5bc-2165-45f7-917f-90b53ee9fb54
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Pollard, Andrew J.
3057c98b-3868-4bbb-a69f-f4660c2afd93